DDInter638 DDInter1376
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Enalapril {u} (Compound) resembles {v} (Compound) Fosinopril
Enalapril {u} (Compound) resembles {v} (Compound) Ramipril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Enalapril {u} (Compound) treats {v} (Disease) coronary artery disease
Enalapril {u} (Compound) binds {v} (Gene) SLC22A7
Enalapril {u} (Compound) upregulates {v} (Gene) LAMA3
Enalapril {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Blood Pressure
Enalapril {u} (Compound) downregulates {v} (Gene) BUB1B
Enalapril {u} (Compound) causes {v} (Side Effect) Serum creatinine increased
Enalapril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Enalapril (Compound) resembles Fosinopril (Compound)
Enalapril (Compound) resembles Ramipril (Compound)
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Enalapril (Compound) treats coronary artery disease (Disease)
Enalapril (Compound) binds SLC22A7 (Gene)
Enalapril (Compound) upregulates LAMA3 (Gene)
Enalapril (Compound) is included by Decreased Blood Pressure (Pharmacologic Class)
Enalapril (Compound) downregulates BUB1B (Gene)
Enalapril (Compound) causes Serum creatinine increased (Side Effect)
Enalapril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate